Holen Sie sich die Stockscreener-App
9.02
0.40%
0.0359
Schlusskurs vom Vortag:
$8.9841
Offen:
$8.81
24-Stunden-Volumen:
7,859
Relative Volume:
0.86
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+27.17%
1M Leistung:
+36.59%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.80
$9.16
1-Wochen-Bereich:
$7.4236
$9.17
52-Wochen-Spanne:
$6.39
$15.35
Leverage Shares 2 X Long Grab Daily Etf Stock (GRAG) Company Profile
Firmenname
Leverage Shares 2 X Long Grab Daily Etf
Sektor
Branche
Telefon
-
Adresse
-
Compare GRAG vs VTI, SPY, IVV, VB, QQQ
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAG
Leverage Shares 2 X Long Grab Daily Etf
|
9.02 | 0 | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
350.21 | 417.53B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
708.72 | 372.57B | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
712.09 | 253.41B | 0 | 0 | 0 | 0.00 |
VB
Vanguard Small Cap Etf
|
286.16 | 160.59B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
646.79 | 124.43B | 0 | 0 | 0 | 0.00 |
Leverage Shares 2 X Long Grab Daily Etf Aktie (GRAG) Neueste Nachrichten
Conquest of Prague Online Stage 2026: Sashi Esport vs. Sinners Map 1 - Coinbase
Northern Colorado vs St. Thomas (MN) - Coinbase
Charlotte at Orlando: Spread - Coinbase
Traffic and trepidation in the Persian Gulf could keep gasoline prices from dropping quickly - Barchart
West Play-In: Golden State at Phoenix - Coinbase
Grab This Brazen Bullish Opportunity in Hard-Hit American Airlines Stock Now - Barchart
Critical Limb Ischemia Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Baxter, Ixaka, Hemostemix Inc., Caladrius Biosciences, Vericel Corporation, Helixmith, Lifecells, LLC - Barchart
Chronic Wounds Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE - Barchart
Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14? - Barchart
An underwater bus in Havana becomes the ride that matters during Cuba's fuel crisis - Barchart.com
GRAG Options Volatility — NASDAQ:GRAG - TradingView
GRAG Options Chain — NASDAQ:GRAG - TradingView
D-Wave Quantum has been cut in halfcan a leveraged ETF help bulls? - MSN
How the Strait of Hormuz ping pong ball is affecting commodity prices from soup to nuts - Barchart.com
Best Oil ETFs in Canada for 2026 - Stocktrades
Most Active Stocks Today: News, Charts, Live Quotes, Graphs - Coinbase
Stock List: Research Stocks from Around the World - GuruFocus
Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight - Barchart.com
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Exocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories - Barchart.com
K2 Gold Receives Positive Record of Decision for Exploration Drilling at the Mojave Project, California - Barchart
Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barchart.com
Stream if You Want to Go Faster: Netflix's New $120 Target - Barchart.com
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart
Systemic Sclerosis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Boehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharma, Kyowa Kirin, GSK, AstraZeneca, Amgen - Barchart.com
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart
7 Best Leveraged ETFs for April 2026 - NerdWallet
Best Easter Products to Sell 2026: 9 Profitable Easter Crafts & Personalized Gift Ideas for Small Business - Barchart.com
UK gathers more than 40 countries to press Iran to reopen the Strait of Hormuz - Barchart.com
Conservatives call for lower gas tax and cuts to 'wasteful spending' to pay for it - Barchart
US-Europe rift widens as Trump lashes out at NATO allies over Mideast war - Barchart
Advocacy groups urge YouTube to protect kids from 'AI slop' videos - Barchart.com
Down 37% in 2026, Dan Ives Says You Should Buy the Dip in Zscaler Stock - Barchart.com
Energy Prices Could Soon ‘Skyrocket.’ Why Cheniere Is One of the Top-Rated Stocks to Buy Now. - Barchart
D-Wave Quantum Has Been Cut in Half—Can a Leveraged ETF Help Bulls? - MarketBeat
Cardi B and Steph Curry earn Webby Award nominations, along with Sydney Sweeney's bathwater - Barchart.com
Del Taco Celebrates National Burrito Day with Free Classic Burritos - Barchart
Is the Explosion of Single-Stock ETFs an Opportunity or a Danger? - MarketBeat
Arm Is Making ‘Bold Moves’ with New In-House Chips and Wall Street Loves It. Why Needham Says You Should Buy ARM Stock Here. - Barchart.com
ROYAL CARIBBEAN'S HERO OF THE SEAS INTRODUCES THE NEXT EVOLUTION OF FAMILY VACATION EXPERIENCES - Barchart.com
Judge won't block meeting that could exempt Gulf drilling from Endangered Species Act - Barchart
10 Inverse ETFs That Gain in a Bear Market - U.S. News Money
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - Barchart.com
Stock Index Futures Rally as Oil Prices Tumble on U.S.-Iran Talks - Barchart.com
Muscle Invasive Bladder Cancer Market Set for Strong Growth Through 2034, Driven by Expanding Pipeline and Innovation | DelveInsight - Barchart
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart
The CLIF Brand Expands Energy Portfolio with New Energy Bites and Limited-Edition Chocolate Berry Energy Bar - Barchart.com
The Growing Risk in Private Credit: Why BlackRock and JPMorgan Are Raising Alarms - Barchart
Tradr 2X Long ASTS Daily ETF ETF Price, Holdings, & News (BATS:ASTX) - MarketBeat
Best-Performing Leveraged ETFs of Last Week - Yahoo Finance
IonQ Just Secured a Deal with the University of Cambridge. Should You Buy the Quantum Computing Stock Here? - Barchart
Finanzdaten der Leverage Shares 2 X Long Grab Daily Etf-Aktie (GRAG)
Es liegen keine Finanzdaten für Leverage Shares 2 X Long Grab Daily Etf (GRAG) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.27%
Kapitalisierung:
|
Volumen (24h):